SRC
TEVA icon

Sage Rhino Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Sage Rhino Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Buy
8,885
+1,011
+13% +$33.7K 0.05% 224
2026
Q1 		$237K Buy
7,874
+417
+6% +$13.4K 0.04% 242
2025
Q4 		$233K Buy
+7,457
New +$184K 0.04% 235

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Sage Rhino Capital's TEVA Position: Q2 2026 in Review

Sage Rhino Capital increased its Teva Pharmaceuticals (TEVA) stake by 13% in Q2 2026, buying an estimated $33.7K and bringing the position to 8,885 shares worth $301K. The position accounts for 0.05% of the portfolio, ranked #224.

Sage Rhino Capital first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Sage Rhino Capital held 8,885 shares of Teva Pharmaceuticals worth $301K as of Q2 2026.
  • Sage Rhino Capital bought 1,011 Teva Pharmaceuticals shares in Q2 2026, an estimated $33.7K.
  • Teva Pharmaceuticals made up 0.05% of Sage Rhino Capital's portfolio in Q2 2026, its #224 holding.
  • Sage Rhino Capital first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.